Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 140 of 140 entries
Sorted by: Best Match Show Resources per page
The 100 000 Genomes Project: bringing whole genome sequencing to the NHS.

BMJ (Clinical research ed.)

Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, Halai D, Baple E, Craig C, Hamblin A, Henderson S, Patch C, O'Neill A, Devereau, Smith K, Martin AR, Sosinsky A, McDonagh EM, Sultana R, Mueller M, Smedley D, Toms A, Dinh L, Fowler T, Bale M, Hubbard T, Rendon A, Hill S, Caulfield MJ.
PMID: 29691228
BMJ. 2018 Apr 24;361:k1687. doi: 10.1136/bmj.k1687.

No abstract available.

Cite
Turnbull C, Scott RH, Thomas E, et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018;361:k1687doi: 10.1136/bmj.k1687.
Turnbull, C., Scott, R. H., Thomas, E., Jones, L., Murugaesu, N., Pretty, F. B., Halai, D., Baple, E., Craig, C., Hamblin, A., Henderson, S., Patch, C., O'Neill, A., Devereau, Smith, K., Martin, A. R., Sosinsky, A., McDonagh, E. M., Sultana, R., Mueller, M., Smedley, D., Toms, A., Dinh, L., Fowler, T., Bale, M., Hubbard, T., Rendon, A., Hill, S., Caulfield, M. J. (2018). The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ (Clinical research ed.), 361k1687. https://doi.org/10.1136/bmj.k1687
Turnbull, Clare, et al. "The 100 000 Genomes Project: bringing whole genome sequencing to the NHS." BMJ (Clinical research ed.) vol. 361 (2018): k1687. doi: https://doi.org/10.1136/bmj.k1687
Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, Halai D, Baple E, Craig C, Hamblin A, Henderson S, Patch C, O'Neill A, Devereau, Smith K, Martin AR, Sosinsky A, McDonagh EM, Sultana R, Mueller M, Smedley D, Toms A, Dinh L, Fowler T, Bale M, Hubbard T, Rendon A, Hill S, Caulfield MJ. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018 Apr 24;361:k1687. doi: 10.1136/bmj.k1687. PMID: 29691228.
Copy Download .nbib Format: NLM
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC.
PMID: 34793200
J Clin Oncol. 2021 Nov 18;JCO2102286. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18.

PURPOSE: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain.PATIENTS AND...

Cite
Gibson CJ, Kim HT, Zhao L, et al. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2021;JCO2102286doi: 10.1200/JCO.21.02286.
Gibson, C. J., Kim, H. T., Zhao, L., Murdock, H. M., Hambley, B., Ogata, A., Madero-Marroquin, R., Wang, S., Green, L., Fleharty, M., Dougan, T., Cheng, C. A., Blumenstiel, B., Cibulskis, C., Tsuji, J., Duran, M., Gocke, C. D., Antin, J. H., Nikiforow, S., DeZern, A. E., Chen, Y. B., Ho, V. T., Jones, R. J., Lennon, N. J., Walt, D. R., Ritz, J., Soiffer, R. J., Gondek, L. P., & Lindsley, R. C. (2021). Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2102286. https://doi.org/10.1200/JCO.21.02286
Gibson, Christopher J, et al. "Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2102286. doi: https://doi.org/10.1200/JCO.21.02286
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2021 Nov 18;JCO2102286. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18. PMID: 34793200.
Copy Download .nbib Format: NLM
Connecting to the Living History of Radiation Exposure.

Journal of the history of biology

Hamblin J, Richards LM.
PMID: 33877498
J Hist Biol. 2021 Apr;54(1):1-6. doi: 10.1007/s10739-021-09634-9. Epub 2021 Apr 20.

No abstract available.

Cite
Hamblin J, Richards LM. Connecting to the Living History of Radiation Exposure. J Hist Biol. 2021;54(1):1-6doi: 10.1007/s10739-021-09634-9.
Hamblin, J., & Richards, L. M. (2021). Connecting to the Living History of Radiation Exposure. Journal of the history of biology, 54(1), 1-6. https://doi.org/10.1007/s10739-021-09634-9
Hamblin, Jacob, and Richards, Linda M. "Connecting to the Living History of Radiation Exposure." Journal of the history of biology vol. 54,1 (2021): 1-6. doi: https://doi.org/10.1007/s10739-021-09634-9
Hamblin J, Richards LM. Connecting to the Living History of Radiation Exposure. J Hist Biol. 2021 Apr;54(1):1-6. doi: 10.1007/s10739-021-09634-9. Epub 2021 Apr 20. PMID: 33877498.
Copy Download .nbib Format: NLM
Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19.

Wellcome open research

Augusto JB, Menacho K, Andiapen M, Bowles R, Burton M, Welch S, Bhuva AN, Seraphim A, Pade C, Joy G, Jensen M, Davies RH, Captur G, Fontana M, Montgomery H, O'Brien B, Hingorani AD, Cutino-Moguel T, McKnight Á, Abbass H, Alfarih M, Alldis Z, Baca GL, Boulter A, Bracken OV, Bullock N, Champion N, Chan C, Couto-Parada X, Dieobi-Anene K, Feehan K, Figtree G, Figtree MC, Finlay M, Forooghi N, Gibbons JM, Griffiths P, Hamblin M, Howes L, Itua I, Jones M, Jardim V, Kapil V, Jason Lee WY, Mandadapu V, Mfuko C, Mitchelmore O, Palma S, Patel K, Petersen SE, Piniera B, Raine R, Rapala A, Richards A, Sambile G, Couto de Sousa J, Sugimoto M, Thornton GD, Artico J, Zahedi D, Parker R, Robathan M, Hickling LM, Ntusi N, Semper A, Brooks T, Jones J, Tucker A, Veerapen J, Vijayakumar M, Wodehouse T, Wynne L, Treibel TA, Noursadeghi M, Manisty C, Moon JC.
PMID: 33537459
Wellcome Open Res. 2020 Oct 12;5:179. doi: 10.12688/wellcomeopenres.16051.2. eCollection 2020.

No abstract available.

Cite
Augusto JB, Menacho K, Andiapen M, et al. Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res. 2020;5:179doi: 10.12688/wellcomeopenres.16051.2.
Augusto, J. B., Menacho, K., Andiapen, M., Bowles, R., Burton, M., Welch, S., Bhuva, A. N., Seraphim, A., Pade, C., Joy, G., Jensen, M., Davies, R. H., Captur, G., Fontana, M., Montgomery, H., O'Brien, B., Hingorani, A. D., Cutino-Moguel, T., McKnight, �. �., Abbass, H., Alfarih, M., Alldis, Z., Baca, G. L., Boulter, A., Bracken, O. V., Bullock, N., Champion, N., Chan, C., Couto-Parada, X., Dieobi-Anene, K., Feehan, K., Figtree, G., Figtree, M. C., Finlay, M., Forooghi, N., Gibbons, J. M., Griffiths, P., Hamblin, M., Howes, L., Itua, I., Jones, M., Jardim, V., Kapil, V., Jason Lee, W. Y., Mandadapu, V., Mfuko, C., Mitchelmore, O., Palma, S., Patel, K., Petersen, S. E., Piniera, B., Raine, R., Rapala, A., Richards, A., Sambile, G., Couto de Sousa, J., Sugimoto, M., Thornton, G. D., Artico, J., Zahedi, D., Parker, R., Robathan, M., Hickling, L. M., Ntusi, N., Semper, A., Brooks, T., Jones, J., Tucker, A., Veerapen, J., Vijayakumar, M., Wodehouse, T., Wynne, L., Treibel, T. A., Noursadeghi, M., Manisty, C., & Moon, J. C. (2020). Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome open research, 5179. https://doi.org/10.12688/wellcomeopenres.16051.2
Augusto, João B, et al. "Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19." Wellcome open research vol. 5 (2020): 179. doi: https://doi.org/10.12688/wellcomeopenres.16051.2
Augusto JB, Menacho K, Andiapen M, Bowles R, Burton M, Welch S, Bhuva AN, Seraphim A, Pade C, Joy G, Jensen M, Davies RH, Captur G, Fontana M, Montgomery H, O'Brien B, Hingorani AD, Cutino-Moguel T, McKnight Á, Abbass H, Alfarih M, Alldis Z, Baca GL, Boulter A, Bracken OV, Bullock N, Champion N, Chan C, Couto-Parada X, Dieobi-Anene K, Feehan K, Figtree G, Figtree MC, Finlay M, Forooghi N, Gibbons JM, Griffiths P, Hamblin M, Howes L, Itua I, Jones M, Jardim V, Kapil V, Jason Lee WY, Mandadapu V, Mfuko C, Mitchelmore O, Palma S, Patel K, Petersen SE, Piniera B, Raine R, Rapala A, Richards A, Sambile G, Couto de Sousa J, Sugimoto M, Thornton GD, Artico J, Zahedi D, Parker R, Robathan M, Hickling LM, Ntusi N, Semper A, Brooks T, Jones J, Tucker A, Veerapen J, Vijayakumar M, Wodehouse T, Wynne L, Treibel TA, Noursadeghi M, Manisty C, Moon JC. Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res. 2020 Oct 12;5:179. doi: 10.12688/wellcomeopenres.16051.2. eCollection 2020. PMID: 33537459; PMCID: PMC7836029.
Copy Download .nbib Format: NLM
Craniopharyngiomas.

Presse medicale (Paris, France : 1983)

Hamblin R, Tsermoulas G, Karavitaki N.
PMID: 34688870
Presse Med. 2021 Oct 22;50(4):104078. doi: 10.1016/j.lpm.2021.104078. Epub 2021 Oct 22.

Craniopharyngiomas are rare epithelial tumours situated primarily in the sellar/parasellar region, occurring along the path of the craniopharyngeal duct. Whilst classed as histologically benign tumours, their unpredictable growth pattern and proximity to vital structures including the optic chiasm, hypothalamus,...

Cite
Hamblin R, Tsermoulas G, Karavitaki N. Craniopharyngiomas. Presse Med. 2021;50(4):104078doi: 10.1016/j.lpm.2021.104078.
Hamblin, R., Tsermoulas, G., & Karavitaki, N. (2021). Craniopharyngiomas. Presse medicale (Paris, France : 1983), 50(4), 104078. https://doi.org/10.1016/j.lpm.2021.104078
Hamblin, Ross, et al. "Craniopharyngiomas." Presse medicale (Paris, France : 1983) vol. 50,4 (2021): 104078. doi: https://doi.org/10.1016/j.lpm.2021.104078
Hamblin R, Tsermoulas G, Karavitaki N. Craniopharyngiomas. Presse Med. 2021 Oct 22;50(4):104078. doi: 10.1016/j.lpm.2021.104078. Epub 2021 Oct 22. PMID: 34688870.
Copy Download .nbib Format: NLM
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

JAMA

Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S.
PMID: 35015038
JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182.

IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown.OBJECTIVE: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a...

Cite
Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022;327(2):129-137doi: 10.1001/jama.2021.23182.
Goldenberg, N. A., Kittelson, J. M., Abshire, T. C., Bonaca, M., Casella, J. F., Dale, R. A., Halperin, J. L., Hamblin, F., Kessler, C. M., Manco-Johnson, M. J., Sidonio, R. F., Spyropoulos, A. C., Steg, P. G., Turpie, A. G. G., Schulman, S. (2022). Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA, 327(2), 129-137. https://doi.org/10.1001/jama.2021.23182
Goldenberg, Neil A, et al. "Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial." JAMA vol. 327,2 (2022): 129-137. doi: https://doi.org/10.1001/jama.2021.23182
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038.
Copy Download .nbib Format: NLM
Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective.

Drug discovery today

Pasqua E, Hamblin N, Edwards C, Baker-Glenn C, Hurley C.
PMID: 34547449
Drug Discov Today. 2021 Sep 20; doi: 10.1016/j.drudis.2021.09.005. Epub 2021 Sep 20.

Despite the devastating impact of many lung diseases on human health, there is still a significant unmet medical need in respiratory diseases, for which inhaled delivery represents a crucial strategy. More guidance on how to design and carry out...

Cite
Pasqua E, Hamblin N, Edwards C, et al. Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug Discov Today. 2021;doi: 10.1016/j.drudis.2021.09.005.
Pasqua, E., Hamblin, N., Edwards, C., Baker-Glenn, C., & Hurley, C. (2021). Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug discovery today, . https://doi.org/10.1016/j.drudis.2021.09.005
Pasqua, Elisa, et al. "Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective." Drug discovery today vol. (2021). doi: https://doi.org/10.1016/j.drudis.2021.09.005
Pasqua E, Hamblin N, Edwards C, Baker-Glenn C, Hurley C. Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug Discov Today. 2021 Sep 20; doi: 10.1016/j.drudis.2021.09.005. Epub 2021 Sep 20. PMID: 34547449.
Copy Download .nbib Format: NLM
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.

Journal of medicinal chemistry

Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM.
PMID: 34510892
J Med Chem. 2021 Sep 23;64(18):13780-13792. doi: 10.1021/acs.jmedchem.1c01102. Epub 2021 Sep 11.

Optimization of a previously reported lead series of PI3Kδ inhibitors with a novel binding mode led to the identification of a clinical candidate compound

Cite
Down K, Amour A, Anderson NA, et al. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. J Med Chem. 2021;64(18):13780-13792doi: 10.1021/acs.jmedchem.1c01102.
Down, K., Amour, A., Anderson, N. A., Barton, N., Campos, S., Cannons, E. P., Clissold, C., Convery, M. A., Coward, J. J., Doyle, K., Duempelfeld, B., Edwards, C. D., Goldsmith, M. D., Krause, J., Mallett, D. N., McGonagle, G. A., Patel, V. K., Rowedder, J., Rowland, P., Sharpe, A., Sriskantharajah, S., Thomas, D. A., Thomson, D. W., Uddin, S., Hamblin, J. N., & Hessel, E. M. (2021). Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. Journal of medicinal chemistry, 64(18), 13780-13792. https://doi.org/10.1021/acs.jmedchem.1c01102
Down, Kenneth, et al. "Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode." Journal of medicinal chemistry vol. 64,18 (2021): 13780-13792. doi: https://doi.org/10.1021/acs.jmedchem.1c01102
Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. J Med Chem. 2021 Sep 23;64(18):13780-13792. doi: 10.1021/acs.jmedchem.1c01102. Epub 2021 Sep 11. PMID: 34510892.
Copy Download .nbib Format: NLM
Showing 133 to 140 of 140 entries